Treatment options

Discover where Amgen can help

Therapy areas

We are investing over $1 billion in our biosimilars program.1 Our biosimilars pipeline, together with our innovative biologics portfolio, cover the therapeutic areas of most need globally. This demonstrates our commitment to therapeutic innovation and patient access to quality medicines.

2014 Top 10 Biologic drugs worldwide2
Biologic AMGEN Originator AMGEN Biosimilar
Humira (adalimumab)   X
Remicade (infliximab)   X
Rituxan (rituximab)   X
Enbrel (etanercept) X  
Lantus (insulin glargine)    
Avastin (bevacizumab)   X
Herceptin (trastuzumab)   X
Neulasta (pegfilgrastim) X  
Lucentis (ranibizumab)    
Avonex (interferon beta-1α)    


Biosimilars pipeline

Amgen is committed to deliver vital medicines in areas where patients need them most, with 10 biosimilars already in development or co-development1†.

Biosimilar Description Reference product condition
ABP 980
Anti HER2 monoclonal antibody • Her2+ metastatic breast cancer
• Her2+ early breast cancer
• Her2+ metastatic gastric cancer
ABP 215
Anti VEGF monoclonal antibody • Metastatic colorectal cancer
• Metastatic breast cancer
• Non-squamous non small-cell lung cancer
• Glioblastoma
• Advanced and/or metastatic renal cell carcinoma
• Ovarian, fallopian tube or primary peritoneal cancer
ABP 798*
Anti - CD20 • Non-Hodgkin's lymphoma
• Choronic lymphocytic leukaemia
• Rheumatoid arthritis
• Granulomatosis with polyangitis and microscopic polyangitis
ABP 494
Anti - EFGR monoclonal antibody • colorectal cancer
• Squamous cell cancer of the head and neck
Biosimilar Description Reference product condition
ABP 501
Anti - TNFα • Plaque psoriasis
• Psoriatic arthritis
• Rheumatoid arthritis
• Axial spondyloarthritis
• Crohn's disease
• Ulcerative colitis
• Polyarticular juvenime idiopathic arthritis
• Active enthesitis-related arthritis
• Hidradenitis suppurativa
• Non-infectious uveitis
ABP 710
Anti - TNFα • Rheumatoid arthritis
• Crohn's disease
• Ulcerative colitis
• Ankylosing spondylitis
• Psoriatic arthritis
• Psoriasis
four programs are currently undisclosed * Developed for both Oncology and Inflammation programs


The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public